NLTX NASDAQ
Seattle, WA 98102
US
Neoleukin Therapeutics, Inc. (NLTX) is a biopharmaceutical enterprise focused on developing immune-based treatments for conditions such as cancer, inflammatory responses, and autoimmune diseases, utilizing its proprietary protein design technology. The company's leading investigational therapy is NL-201, a novel protein meticulously crafted to emulate the therapeutic effects of the IL-2/IL-15 cytokines. This product candidate is intended for the management of various malignancies, including renal cell carcinoma and melanoma. The organization, founded in 2003, was previously known as Aquinox Pharmaceuticals, Inc. before officially changing its name to Neoleukin Therapeutics, Inc. in August 2019. Its operations are based out of Seattle, Washington.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Woods Robert Keith | A-Award | 15,400 | $32.30 | 2024-01-16 |
| PALEKAR ROHAN | A-Award | 15,400 | $32.30 | 2024-01-16 |
| Noonberg Sarah B. | A-Award | 15,400 | $32.30 | 2024-01-16 |
| Freedland Cory S. | A-Award | 15,400 | $32.30 | 2024-01-16 |
| BAFFI ROBERT | A-Award | 15,400 | $32.30 | 2024-01-16 |